scholarly journals The Effect of Vitamin D Supplementation on Anthropometric Indices and Total Testosterone in Women with Polycystic Ovary Syndrome Treated with Low Calorie Diet: A Randomized Clinical Trial

2019 ◽  
Vol 12 (11) ◽  
pp. 10-22
Author(s):  
Samira Jafari-Sfidvajani ◽  
Roghayeh Ahangari ◽  
Mohammad Hozoori ◽  
Hassan Mozaffari-Khosravi ◽  
Hossein Fallahzadeh ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Vitamin D Supplementation ◽  
Total Testosterone ◽  
Ovary Syndrome ◽  
Anthropometric Indices ◽  
Low Calorie Diet ◽  
Calorie Diet

The role of vitamin D in metabolic and reproductive disturbances of polycystic ovary syndrome: A narrative mini-review

2020 ◽  
pp. 1-8
Author(s):  
Daniela Menichini ◽  
Gianpiero Forte ◽  
Beatrice Orrù ◽  
Giuseppe Gullo ◽  
Vittorio Unfer ◽  
...  
Keyword(s):  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Embryo Quality ◽  
Polycystic Ovary ◽  
Vitamin D Supplementation ◽  
Endometrial Receptivity ◽  
Metabolic Disturbances ◽  
Ovary Syndrome ◽  
Beneficial Role

Abstract. Vitamin D is a secosteroid hormone that plays a pivotal role in several metabolic and reproductive pathways in humans. Increasing evidence supports the role of vitamin D deficiency in metabolic disturbances and infertility in women with polycystic ovary syndrome (PCOS). Indeed, supplementation with vitamin D seems to have a beneficial role on insulin resistance and endometrial receptivity. On the other hand, exceedingly high levels of vitamin D appear to play a detrimental role on oocytes development and embryo quality. In the current review, we summarize the available evidence about the topic, aiming to suggest the best supplementation strategy in women with PCOS or, more generally, in those with metabolic disturbances and infertility. Based on the retrieved data, vitamin D seems to have a beneficial role on IR, insulin sensitivity and endometrial receptivity, but high levels and incorrect timing of administration seem to have a detrimental role on oocytes development and embryo quality. Therefore, we encourage a low dose supplementation (400–800 IU/day) particularly in vitamin D deficient women that present metabolic disturbances like PCOS. As far as the reproductive health, we advise vitamin D supplementation in selected populations, only during specific moments of the ovarian cycle, to support the luteal phase. However, ambiguities about dosage and timing of the supplementation still emerge from the clinical studies published to date and further studies are required.

scholarly journals Effects of vitamin D supplementation on serum lipid profile in women with polycystic ovary syndrome

Medicine ◽  
2020 ◽  
Vol 99 (23) ◽  
pp. e20621
Author(s):  
Xiao-yan Shi ◽  
Jia Yao ◽  
Si-min Fan ◽  
Pei-pei Hong ◽  
Yu-guo Xia ◽  
...  
Keyword(s):  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Lipid Profile ◽  
Serum Lipid ◽  
Polycystic Ovary ◽  
Vitamin D Supplementation ◽  
Serum Lipid Profile ◽  
Ovary Syndrome

scholarly journals Atorvastatin Increases 25-Hydroxy Vitamin D Concentrations in Patients with Polycystic Ovary Syndrome

2010 ◽  
Vol 56 (11) ◽  
pp. 1696-1700 ◽  
Author(s):  
Thozhukat Sathyapalan ◽  
John Shepherd ◽  
Charlotte Arnett ◽  
Anne-Marie Coady ◽  
Eric S Kilpatrick ◽  
...  
Keyword(s):  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Statin Treatment ◽  
Vitamin D Supplementation ◽  
Significant Rise ◽  
Controlled Study ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Markers Of Inflammation

BACKGROUND It has been shown that many women with polycystic ovary syndrome (PCOS) are 25-hydroxyvitamin D (25OHD) insufficient. Both statin treatment and vitamin D supplementation have been shown to improve biochemical hyperandrogenemia, insulin resistance, and markers of inflammation in patients with PCOS, raising the possibility that some of the statin effects are mediated through vitamin D. METHODS We conducted this randomized, double-blind placebo controlled study to assess the effect of atorvastatin on serum 25OHD concentrations in patients with PCOS. Forty medication-naive patients with PCOS were randomized to either atorvastatin 20 mg daily or placebo for 3 months. After completing the initial 3 months of atorvastatin or placebo, both groups of patients participated in a 3-month extension study with metformin 1500 mg daily. We measured changes in 25OHD concentrations by use of tandem mass spectrometry. RESULTS Mean (SD) baseline 25OHD concentrations were comparable between the 2 groups [45.9 (2.4) vs 44.8 (1.8) nmol/L; P = 0.7]. There was a significant increase in 25OHD concentrations with atorvastatin [45.9 (2.4) vs 60.8 (3.5) nmol/L] compared with placebo [44.8 (1.8) vs 41.8 (3.2) nmol/L; P = 0.02]. Three-month treatment with metformin maintained the improvement of 25OHD with atorvastatin compared to baseline [45.9 (2.4) vs 61.8 (3.5), P ≤ 0.01). There were no significant changes in 25OHD concentrations in the placebo group after 12 weeks of metformin. CONCLUSIONS Among patients with polycystic ovary syndrome, 12 weeks of atorvastatin led to a clinically significant rise in 25OHD concentrations. This may represent a beneficial pleiotropic effect of statins on 25OHD concentrations.

scholarly journals Vegan or Low Calorie Diet for Weight Loss in Polycystic Ovary Syndrome Females: A Randomised Controlled Study

2020 ◽  
Vol 14 (1-2) ◽  
Author(s):  
Shubhra Saraswat
Keyword(s):  
Weight Loss ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Randomized Study ◽  
Vegan Diet ◽  
Controlled Study ◽  
Ovary Syndrome ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet

ABSTRACT The primary aim of this randomized study is to find the effect of a diet based intervention (vegan diet and low-calorie diet) among women suffering from polycystic ovary syndrome (PCOS). Overweight and obese (BMI- 33.7 ± 4.8 kg/m2) women with PCOS (n = 21; age, 33.1 ± 4.4 years) were assessed to participate in a 90 days randomized weight loss study delivered and guided through diet and nutrition counseling (personalized and group). Body weight, BMI and waist circumference and dietary intakes were assessed three times at 0, 45 and 90 days. It was hypothesized that weight loss would be more in the vegan group. All data were statistically analyzed and presented as median (inter quartile range). Vegan participants reported significant weight loss at Day 90, “1.8% (“5.0%, “0.9%) vegan, 0.0% (“1.2%, 0.3%) low-cal; P = .04), Vegan participants showed a greater decrease in energy (“265 (“469, 0)) kcal/d) and fat intake “8.2% (“9.8%, 0%) energy) at Day 90 compared with low-cal participants (0 (0, 173)) kcal/d, P = .02; 0 (0, 3.7%) energy, P = .02). The results suggest that following a vegan diet can be more effective for achieving weight loss in addition to better nutrient intake profile in women with PCOS; however, a bigger sample size is required to validate these results.

Sign in / Sign up

Export Citation Format

Share Document